ClinicalTrials.gg
CompletedNCT06367686DISCOUpdated Jun 11, 2026

Detecting Systemic Carbon Dioxide Levels With a Novel Biosensor

An observational study in Hypercapnic Respiratory Failure, Pulmonary Disease, Chronic Obstructive and Neuromuscular Diseases, sponsored by The Hospital of Vestfold. Completed at 1 site in Norway. Open to participants aged 18 Years to 110 Years. Per ClinicalTrials.gov, last updated 2026-06-11.

Primary conditionObesity Hypoventilation SyndromeRegistry: Respiratory InsufficiencyReclassifiedWhy we changed it
Registry
Respiratory Insufficiency — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity Hypoventilation Syndrome
Why
  1. The study's listed conditions name Obesity Hypoventilation Syndrome, a narrower term within Respiratory Insufficiency.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by The Hospital of Vestfold · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
21
Ages
18 Years to 110 Years
Sex
All
01

Study summary

The study is an open, prospective, single center clinical observational pilot investigation. The aim is to compare the carbon dioxide values measured by the IscAlert sensor, which is inserted in proximity to the nasal mucosa. The study wants to investigate if the nasal mucosa application and measurements are feasible, what kind of possible complications such a measurement can cause, and if the measurements can be a surrogate marker for systemic carbon dioxide values.

Read the detailed description

he study is an open, prospective, single center clinical observational pilot investigation including 9 patients and 2 healthy volunteers. The aim is to compare the carbon dioxide values measured by the IscAlert sensor, which is inserted in proximity to the nasal mucosa, with the transcutaneous carbon dioxide values measured at the forehead by a transcutaneous carbon dioxide-monitor, the arterial carbon dioxide measurements performed by blood gas analyses, and carbon dioxide measurements registered with the IscAlert sensor implanted in the muscle of the forearm. The study wants to investigate if the nasal mucosa application and measurements are feasible, what kind of possible complications such a measurement can cause, and if the measurements can be a surrogate marker for systemic carbon dioxide values. The study will include patients with a tendency to hypoventilation, thereby giving rise to a carbon dioxide retention; 3 patients with chronic obstructive pulmonary disease with suspected hypercapnic respiratory failure who are evaluated for non-invasive mask-treatment and long-term oxygen treatment supply if needed. 3 patients with neuromuscular disorders and 3 patients with obesity hypoventilation syndrome who are evaluated for non-invasive mask treatment. The measurements will last for about 8 to 14 hours at night while the patients are sleeping. In addition, the study will also include 2 healthy volunteers as a control group. They will have the equipment mounted on them for about 8 hours during the day in connection with normal office work. Follow up by telephone 7 days +/-2 days after the measurements are finished. The inclusion period is expected to be about 9 months.

02

Conditions studied

  • Hypercapnic Respiratory Failure
  • Pulmonary Disease, Chronic Obstructive
  • Neuromuscular Diseases
  • Obesity Hypoventilation Syndrome (OHS)
03

In context

Obesity Hypoventilation Syndrome Reclassified

74 studies on the registry are indexed under Obesity Hypoventilation Syndrome; 11 are open to participants now.

This study's enrollment of 21 is below the median of 50 across 25 observational studies indexed under Obesity Hypoventilation Syndrome.

Browse Obesity Hypoventilation Syndrome studies →

Lead sponsor

The Hospital of Vestfold is the lead sponsor of 16 studies on the registry; 2 are open to participants now.

Compared within Obesity Hypoventilation Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Respiratory Insufficiency. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 110 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Nine patients will be selected consequtive from the hypoventilation assessment planning program at the site. Additionally, two healthy individuals, who have no heart-, lung-, or circulatory diseases, no bleeding disorder, no sleep disorders, and no ties whatsoever to the sponsor (Sensocure AS), will be included as volunteers. Otherwise completely freely chosen by the investigators except they must not have any kind of (direct or indirect) acquaintanceship to the investigators. Eligible subjects will be invited to participate in this clinical investigation. All the subjects will be included at least one day before study procedure starts.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The subject must meet all of the following inclusion criteria at the time of enrolment:

EITHER

  1. Patient are at risk of hypoventilation and thus carbon dioxide retention.
  2. Either

    1. Under evaluation for treatment with non-invasive ventilation and maybe Long term oxygen treatment due to or
    2. Under evaluation for non-invasive ventilation support due to Obesity hypoventilation syndrome or due to a neuromuscular disorder.

    OR

  3. Healthy volunteers

    ALL subjects:

  4. Subject must be 18 years or older
  5. Subject must be able to give written

Exclusion criteria

Exclusion Criteria:

  1. Known allergy to local anesthetics.
  2. Participants should not have any kind of (direct or indirect) affiliation to Sensocure AS
  3. Healthy volunteers: No heart-, lung-, or circulatory diseases, no bleeding disorder, no sleep disorders
  4. Healthy volunteers should not have any kind of (direct or indirect) acquaintanceship to the investigators
  5. Active smoker/use of snuff
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
21 participants (actual)
Patient registry
No

Groups and cohorts

  • Chronic obstructive pulmonary disease

    3 Chronic obstructive pulmonary disease patients monitored with IscAlert sensor at nasal mucosa for 8-14 hours during the night

    Device: IscAlert sensor

  • Neuromuscular disease

    3 Neuromuscular disease patients monitored with IscAlert sensor at nasal mucosa for 8-14 hours during the night

    Device: IscAlert sensor

  • Obesity hypoventilation syndrome

    3 Obesity hypoventilation syndrome patients monitored with IscAlert sensor at nasal mucosa for 8-14 hours during the night

    Device: IscAlert sensor

  • Healthy volunteers

    2 healthy volunteers monitored with IscAlert sensor at nasal mucosa for approximately 8 hours during daytime

    Device: IscAlert sensor

Interventions

  • DeviceIscAlert sensor

    Insertion of an IscAlert sensor at the nasal mucosa

06

What researchers measure

Primary outcomes

  1. Partial pressure (level) of carbon dioxide at the nasal mucosa

    Nasal mucosa's partial pressure of carbon dioxide (kPa) during insertion period

    Time frame: 14 hours

Secondary outcomes

  1. Bleeding

    Amount of blood from insertion site (ml)

    Time frame: 7 days

  2. Infection

    Infection from insertion site at the discretion of the investigator (yes or no)

    Time frame: 7 days

  3. Sinusitis

    Developement of sinusitis at the discretion of the investigator (yes or no)

    Time frame: 7 days

  4. Ulceration

    Developement of ulceration at the nasal mucosa at the discretion of the investigator (yes or no)

    Time frame: 7 days

  5. Pain at sensor insertion site

    Pain at the insertion site measured by Numeric Rating Scale (0= no pain, 10= maximum pain)

    Time frame: 7 days

Other outcomes

  1. Muscular temperature level

    Muscular temperature level (grade Celsius) during insertion period

    Time frame: 14 hours

  2. Nasal temperature level

    Nasal temperature level (grade Celsius) during insertion period

    Time frame: 14 hours

  3. Temporal temperature level

    Temporal temperature level (grade Celsius) during insertion period

    Time frame: 14 hours

  4. IscAlert functionality

    Number of hours with a well-functioning sensor (giving carbon dioxide- and temperature data)

    Time frame: 14 hours

  5. Number of pack-years

    Smoking habit; number of pack-years by participants

    Time frame: 7 days

  6. Length of sensor implantation time

    Length of sensor implantation time during hospitalisation

    Time frame: 7 days

  7. Peripheral oxygen saturation

    Peripheral oxygen saturation (SpO2)

    Time frame: 14 hours

  8. Arterial partial pressure (level) of carbon dioxide

    Arterial partial pressure of carbon dioxide (kPa) during insertion period - measured in arterial blood

    Time frame: 14 hours

  9. Arterial partial pressure (level) of oxygen

    Arterial partial pressure of oxygen (kPa) during insertion period - measured in arterial blood

    Time frame: 14 hours

  10. Intramuscular partial pressure (level) of carbon dioxide

    Intramuscular partial pressure of carbon dioxide (kPa) during insertion period - measured in the forearm

    Time frame: 14 hours

  11. Transcutaneous partial pressure (level) of carbon dioxide

    Transcutaneous partial pressure of carbon dioxide (kPa) during insertion period, measured at the skin of the forehead

    Time frame: 14 hours

  12. Patient-Reported Outcome Measures 1a - discomfort

    Discomfort in the nose - Patient-Reported Outcome Measure, Scale 1 to 5 (1= no, 2= little, 3=Some, 4=very 5=Extreme)

    Time frame: 14 hours

  13. Patient-Reported Outcome Measures 1b - discomfort

    Discomfort in the nose - Patient-Reported Outcome Measure, Scale 1 to 5 (1= no, 2= little, 3=Some, 4=very 5=Extreme)

    Time frame: 7 days

  14. Patient-Reported Outcome Measures 2a - runny nose

    Runny nose - Patient-Reported Outcome Measure, Scale 1 to 5 (1= no, 2= little, 3=Some, 4=very 5=Extreme)

    Time frame: 14 hours

  15. Patient-Reported Outcome Measures 2b - runny nose

    Runny nose - Patient-Reported Outcome Measure, Scale 1 to 5 (1= no, 2= little, 3=Some, 4=very 5=Extreme)

    Time frame: 7 days

  16. Patient-Reported Outcome Measures 3a - sneezing

    Sneezing - Patient-Reported Outcome Measure, Scale 1 to 5 (1= no, 2= little, 3=Some, 4=very 5=Extreme)

    Time frame: 14 hours

  17. Patient-Reported Outcome Measures 3b - sneezing

    Sneezing - Patient-Reported Outcome Measure, Scale 1 to 5 (1= no, 2= little, 3=Some, 4=very 5=Extreme)

    Time frame: 7 days

  18. Patient-Reported Outcome Measures 3b - Ulceration

    Ulceration in the nose mucouse membrane - Patient-Reported Outcome Measure, Scale 1 to 5 (1= no, 2= little, 3=Some, 4=very 5=Extreme)

    Time frame: 7 days

  19. Patient-Reported Outcome Measures 3a - Ulceration

    Ulceration in the nose mucouse membrane - Patient-Reported Outcome Measure, Scale 1 to 5 (1= no, 2= little, 3=Some, 4=very 5=Extreme)

    Time frame: 14 hours

  20. Patient-Reported Outcome Measures 4a - tenderness

    Tenderness in the nose - Patient-Reported Outcome Measure, Scale 1 to 5 (1= no, 2= little, 3=Some, 4=very 5=Extreme)

    Time frame: 14 hours

  21. Patient-Reported Outcome Measures 4b - tenderness

    Tenderness in the nose - Patient-Reported Outcome Measure, Scale 1 to 5 (1= no, 2= little, 3=Some, 4=very 5=Extreme)

    Time frame: 7 days

  22. Patient-Reported Outcome Measures 5b - bleeding

    Bleeding from the nose - Patient-Reported Outcome Measure, Scale 1 to 5 (1= no, 2= little, 3=Some, 4=very 5=Extreme)

    Time frame: 7 days

  23. Patient-Reported Outcome Measures 5a - bleeding

    Bleeding from the nose - Patient-Reported Outcome Measure, Scale 1 to 5 (1= no, 2= little, 3=Some, 4=very 5=Extreme)

    Time frame: 14 hours

  24. Patient-Reported Outcome Measures 6a - reduced sense of smell

    Reduced sense of smell - Patient-Reported Outcome Measure, Scale 1 to 5 (1= no, 2= little, 3=Some, 4=very 5=Extreme)

    Time frame: 14 hours

  25. Patient-Reported Outcome Measures 6b - reduced sense of smell

    Reduced sense of smell - Patient-Reported Outcome Measure, Scale 1 to 5 (1= no, 2= little, 3=Some, 4=very 5=Extreme)

    Time frame: 7 days

  26. Patient-Reported Outcome Measures 7b - reduced sense of taste

    reduced sense of taste - Patient-Reported Outcome Measure, Scale 1 to 5 (1= no, 2= little, 3=Some, 4=very 5=Extreme)

    Time frame: 7 days

  27. Patient-Reported Outcome Measures 7a - reduced sense of taste

    reduced sense of taste - Patient-Reported Outcome Measure, Scale 1 to 5 (1= no, 2= little, 3=Some, 4=very 5=Extreme)

    Time frame: 14 hours

  28. Patient-Reported Outcome Measures 8a - difficulty sleeping

    difficulty sleeping - Patient-Reported Outcome Measure, Scale 1 to 5 (1= no, 2= little, 3=Some, 4=very 5=Extreme)

    Time frame: 14 hours

  29. Patient-Reported Outcome Measures 8b - easy to wake up while sleeping

    easy to wake up while sleeping - Patient-Reported Outcome Measure, Scale 1 to 5 (1= no, 2= little, 3=Some, 4=very 5=Extreme)

    Time frame: 7 days

  30. Patient-Reported Outcome Measures 9 - problems with eating and drinking

    problems with eating and drinking - Patient-Reported Outcome Measure, Scale 1 to 5 (1= no, 2= little, 3=Some, 4=very 5=Extreme)

    Time frame: 14 hours

  31. Patient-Reported Outcome Measures 10 - difficult breathing

    difficult breathing - Patient-Reported Outcome Measure, Scale 1 to 5 (1= no, 2= little, 3=Some, 4=very 5=Extreme)

    Time frame: 14 hours

  32. Patient-Reported Outcome Measures 11a - diagnosed infection in the nose or sinuses

    diagnosed infection in the nose or sinuses - Patient-Reported Outcome Measure, Scale 1 to 2 (1= No, 2= Yes)

    Time frame: 14 hours

  33. Patient-Reported Outcome Measures 11b - diagnosed infection in the nose or sinuses

    diagnosed infection in the nose or sinuses - Patient-Reported Outcome Measure, Scale 1 to 2 (1= No, 2= Yes)

    Time frame: 7 days

07

Study locations

1 site
  • Vestfold Hopsital Trust
    Tønsberg, 3103, Norway
08

References and documents

Individual participant data

Plan to share: No — No plan to share IPD to other researchers

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2025 to primary completion in Mar 2026, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2024
First posted
Apr 16, 2024
StartActual
Jan 30, 2025
Primary completionActual
Mar 16, 2026
CompletionActual
Mar 16, 2026
Last update
Jun 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06367686
Lead sponsor
The Hospital of Vestfold
Collaborators
Sensocure AS
Responsible party
Anne-Marie Gabrielsen (Senior consultant, The Hospital of Vestfold) — Principal investigator
First posted
Apr 16, 2024
Start date
Jan 30, 2025
Primary completion
Mar 16, 2026
Completion
Mar 16, 2026
Last update
Jun 11, 2026

Study contacts

Anne-Marie Gabrielsen, MD, PhD
principal investigator · The Hospital of Vestfold

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion